JP2017502003A5 - - Google Patents

Download PDF

Info

Publication number
JP2017502003A5
JP2017502003A5 JP2016538037A JP2016538037A JP2017502003A5 JP 2017502003 A5 JP2017502003 A5 JP 2017502003A5 JP 2016538037 A JP2016538037 A JP 2016538037A JP 2016538037 A JP2016538037 A JP 2016538037A JP 2017502003 A5 JP2017502003 A5 JP 2017502003A5
Authority
JP
Japan
Prior art keywords
phe
pro
tyr
aib
nal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016538037A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017502003A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/077240 external-priority patent/WO2015086686A2/en
Publication of JP2017502003A publication Critical patent/JP2017502003A/ja
Publication of JP2017502003A5 publication Critical patent/JP2017502003A5/ja
Pending legal-status Critical Current

Links

JP2016538037A 2013-12-13 2014-12-10 プロテアーゼ耐性ペプチド Pending JP2017502003A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361915662P 2013-12-13 2013-12-13
US61/915,662 2013-12-13
PCT/EP2014/077240 WO2015086686A2 (en) 2013-12-13 2014-12-10 Protease resistant peptides

Publications (2)

Publication Number Publication Date
JP2017502003A JP2017502003A (ja) 2017-01-19
JP2017502003A5 true JP2017502003A5 (enExample) 2017-12-28

Family

ID=52021207

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016538037A Pending JP2017502003A (ja) 2013-12-13 2014-12-10 プロテアーゼ耐性ペプチド

Country Status (11)

Country Link
US (1) US20160318987A1 (enExample)
EP (2) EP3080153A2 (enExample)
JP (1) JP2017502003A (enExample)
KR (1) KR20160098406A (enExample)
CN (1) CN105849123A (enExample)
AU (1) AU2014363547A1 (enExample)
BR (1) BR112016013157A2 (enExample)
CA (1) CA2933405A1 (enExample)
MX (1) MX2016007407A (enExample)
SG (1) SG10201805039UA (enExample)
WO (1) WO2015086686A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI726889B (zh) 2015-06-10 2021-05-11 英商梅迪繆思有限公司 蛋白酶抗性之脂化肽
AU2016343775B2 (en) 2015-10-28 2021-07-29 Tufts Medical Center Novel polypeptides with improved proteolytic stability, and methods of preparing and using same
KR20190017017A (ko) 2016-06-09 2019-02-19 메디뮨 리미티드 프로테아제-내성 모노-지질화된 펩타이드
EP4092038A1 (en) 2017-09-11 2022-11-23 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
ES2980707T3 (es) 2018-04-05 2024-10-02 Sun Pharmaceutical Ind Ltd Nuevos análogos de GLP-1
JP7736315B2 (ja) * 2020-03-31 2025-09-09 アンタロス メディカル アクティエボラーグ イメージング及び治療目的のキレート部分を含む選択的gip受容体アゴニスト
IL303578A (en) * 2020-12-16 2023-08-01 Medimmune Ltd Polypeptides and their uses
TW202346323A (zh) * 2022-02-07 2023-12-01 英商梅迪繆思有限公司 具有改善的生物穩定性的glp—1及升糖素雙重激動肽

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1495198A (zh) * 1998-12-07 2004-05-12 �о���Ӧ�ÿ�ѧЭ��ɷ����޹�˾ 胰高血糖素样肽-1的类似物
CA2641053A1 (en) * 2006-02-08 2007-08-16 Lonza Ag Synthesis of glucagon-like peptide
EP2021014A1 (en) * 2006-05-26 2009-02-11 Brystol-Myers Squibb Company Sustained release glp-1 receptor modulators
US20090318353A1 (en) * 2006-08-25 2009-12-24 Novo Nordisk A/S Acylated Exendin-4 Compounds
CA2707448C (en) * 2007-12-11 2014-10-14 Cadila Healthcare Limited Peptidomimetics with glucagon antagonistic and glp-1 agonistic activities
ES2354488T3 (es) * 2008-04-18 2011-03-15 F. Hoffmann-La Roche Ag Alfa-n-metilación de aminoácidos.
US20120264685A1 (en) * 2009-10-22 2012-10-18 Rajesh Bahekar Short chain peptidomimetics based orally active glp 1 agonist and glucagon receptor antagonist
US20130143800A1 (en) * 2011-11-07 2013-06-06 Research Development Foundation Combination therapies to treat diabetes
AR092873A1 (es) * 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
JP2016506391A (ja) * 2012-12-06 2016-03-03 ステルス ペプチドズ インターナショナル インコーポレイテッド ペプチド治療薬およびその使用方法

Similar Documents

Publication Publication Date Title
JP2017502003A5 (enExample)
AR096162A1 (es) Péptidos terapéuticos
TWI455721B (zh) 癌疫苗組合物
NZ600732A (en) Oxyntomodulin peptide analogue
SA518390954B1 (ar) لقاحات علاجية لفيروس الورم الحليمي البشري 18
RU2021134101A (ru) Модифицированная j-цепь
PE20121393A1 (es) Analogo peptidico de oxintomodulina
PH12013500050A1 (en) Anticancer fusion protein
TW201613958A (en) MIC-1 fusion proteins and uses thereof
NZ624533A (en) Novel immunotherapy against several tumors including neuronal and brain tumors
WO2015188132A8 (en) Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof
PH12014501083A1 (en) Anticancer fusion protein
CN106232616A (zh) 两亲性合成抗菌肽、其药物组合物及其用途
JP2017522362A5 (enExample)
NZ708990A (en) Method for activating helper t cell
MX2024006356A (es) Metodos para predecir la utilidad de modificaciones de aminoacidos especificas de una enfermedad para inmunoterapia
JP2019525753A5 (enExample)
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
AR096927A1 (es) INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7
CO2019013768A2 (es) Compuestos de mic-1 y usos de estos
PH12014501363A1 (en) Anticancer fusion protein
WO2013096868A3 (en) Saposin-a derived peptides and uses thereof
SA521421371B1 (ar) لقاحات الببتيد
WO2012174397A3 (en) Anti-inflammatory pharmaceutical products
MX337756B (es) Peptido de epitope hig2 y urlc10 y vacunas que contienen el mismo.